New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 18, 2014
09:00 EDTACRXAcelRx attractive ahead of Zalviso PDUFA, says Roth Capital
Roth Capital believes that AcelRx's Zalviso has the potential to replace IV PCA across many U.S. hospitals for treating patients with moderate-to-severe pain. The firm thinks the drug is likely to be approved next week and views the stock's recent weakness as a buying opportunity.
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 13, 2014
07:08 EDTACRXAcelRx to present positive efficacy results in Phase 3 trial of Zalviso
AcelRx Pharmaceuticals will present safety and efficacy data from a Phase 3 pivotal trial evaluating the Zalviso sufentanil sublingual tablet system for the treatment of moderate-to-severe acute pain following joint replacement surgery at the American Society of Regional Anesthesia and Pain Medicine 13th Annual Pain Medicine Meeting on November 13th to November 16th in San Francisco. Data from the sublingual sufentanil tablet system development program highlights efficacy across various demographic populations
November 11, 2014
10:20 EDTACRXHigh option volume stocks
High option volume stocks: RLGY TWC LITB SPM ACRX JWN OCR CALL CST ERIC
November 10, 2014
16:16 EDTACRXAcelRx sees FY14 R&D expenses $25M-$27M
Subscribe for More Information
16:15 EDTACRXAcelRx reports Q3 EPS (13c), consensus (22c)
Reports Q3 revenue $4.83M, consensus $4.43M.
07:12 EDTACRXAcelRx receives ISO certification of its quality management system
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use